Hologic Inc. (HOLX)
HOLX's Genius AI Mammography Flags Missed Breast Cancer Cases
Hologic shares dip as the company unveils new study data showing its Genius AI mammography flags 32% of previously missed breast cancer cases.
Why Hologic (HOLX) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Hologic's Genius AI Detection Shows Value by Spotting Missed Cancers
HOLX's Genius AI Detection flags missed breast cancers, showing promise in improving mammography accuracy and radiologist efficiency.
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
What Is Driving Hologic's Strength in the US Diagnostics Market?
HOLX's Diagnostics gains accelerate as U.S. molecular testing drives growth and new Panther Fusion and Genius platform approvals widen its runway.
HOLX Stock Up 16% in 6 Months: Is it Still a Hold Heading Into 2026?
Hologic shares rise 16% in six months, with divisional strength clinical data and a go-private deal shaping the short-term outlook.
Hologic's BCI Test Shows Growing Impact in Endocrine Therapy Decisions
HOLX's BCI test gains traction as new SABCS studies are set to highlight its growing role in guiding extended endocrine therapy decisions.
Why Is Hologic (HOLX) Up 1% Since Last Earnings Report?
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
HOLX vs. DGX: Which Healthcare Diagnostics Stock Is the Better Bet?
DGX's strong YTD gains and momentum in advanced diagnostics and acquisitions highlight why it may stand out in the competitive testing market against HOLX.
Here's Why Hologic (HOLX) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
New Clinical Evidence Bolsters Hologic's Breast Cancer Technologies
HOLX is set to present new real-world data at RSNA 2025, showing how its AI-driven breast imaging tools boost workflow without sacrificing detection.
